GlassScriptPhysician profile
Firdos Sheikh
NPI 1205922333
$1,138.67
in general payments reported to CMS, 2019-2025
14 companies · $53.29 in 2025
The $53.29 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $242 · 2022: $86.08 · 2023: $125 · 2024: $106 · 2025: $53.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $284.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $331.10 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2023 | Abilify Maintena, Abilify Asimtufii |
| Gilead Sciences, INC. | $121.87 | 2020 | |
| Glaxosmithkline, LLC. | $119.82 | 2020 | |
| Abbvie INC. | $89.87 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $86.08 | 2022 | |
| Lilly USA, LLC | $66.64 | 2024 | |
| Novartis Pharmaceuticals Corporation | $63.72 | 2019 | |
| Ucb, INC. | $47.25 | 2019-2024 | Briviact |
| Genzyme Corporation | $23.33 | 2019 | |
| Livanova USA, INC. | $20.99 | 2019 | |
| Kyowa Kirin, INC. | $16.04 | 2024 | Nourianz |
| Vertical Pharmaceuticals, LLC | $13.60 | 2019 | |
| Boston Scientific Corporation | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firdos Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.